Who
Mark J. Newman
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, GeoVax Labs.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 0
- Bought
- $9,890
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Jun 2010
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,600 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 1 Aug 2023filed 14 Aug 2023 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 7 Dec 2021filed 8 Dec 2021 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,700 at $0.00 | filing |
| 11 Aug 2021filed 11 Aug 2021 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 10 Dec 2010filed 28 Dec 2010 | GOVX GeoVax Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 Jun 2010filed 14 Jun 2010 | GOVX GeoVax LabsBiotechnology | SEC FORM 4 Bought | $3,2501,000 at $3.25 | filing |
| 11 Jun 2010filed 14 Jun 2010 | GOVX GeoVax LabsBiotechnology | SEC FORM 4 Bought | $6,6402,000 at $3.32 | filing |
News
Lisata Therapeutics (NASDAQ:LSTA) & GeoVax Labs (NASDAQ:GOVX) Head to Head ContrastGOVX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Mark J. Newman; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.